Launch of a data management platform to improve neurotherapeutic research

20 December 2021

1 min read

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

Neuroscience company Inscopix, Inc. introduced a cloud-based data management system to make it easier to collect, organize, and share neuroscience research.

“Inscopix has built a revolutionary integrated technology [that] will enable scientists to create standardized and customizable workflows that can analyze, store and share datasets in all modalities – from imagery to behavior to electrophysiology – and to deepen understanding of the brain ”, said the CEO of Ascopix. Kunal Ghosh, PhD, said in a company statement. “This artificial intelligence-based platform will help researchers reduce data analysis times from months to weeks or even hours; quickly share and synchronize results with your colleagues; and energize the potential of these imaging technologies to reveal clinically predictive and accurate preclinical models for the discovery and development of the next generation of neurotherapeutics.

Called Inscopix Data Exploration, Analysis and Sharing (IDEAS), the platform aims to help the entire neuroscience community to process and analyze data from behavioral tools, electrophysiology, photonic imaging, microscopy and functional MRI (fMRI). Centralizing information with new technology will allow users to retrieve the data needed for a wide variety of tasks securely and much faster than traditional methods of storing data in large files located in places where a single user can. to access.

“Next-generation imaging technologies are incredibly data rich and frequently require robust data science and analytics solutions to maximize their potential. IDEAS is a significant breakthrough that links the arc between our expertise in neuroscientific imaging tools and the discovery of therapeutic drugs ”, David Gray, PHD, Inscopix Scientific Director, noted in the press release.

“We are excited to be working with other translation-focused collaborators to catalyze the application of new high throughput in vivo assays with IDEAS,” said Gray.